Biological and Functional Changes in Healthy Adult Smokers Who Are Continuously Abstinent From Smoking for One Year: Protocol for a Prospective, Observational, Multicenter Cohort Study

Cam Tuan Tran, Loyse Felber Medlin, Nicola Lama, Brindusa Taranu, Weeteck Ng, Christelle Haziza, Patrick Picavet, Gizelle Baker, Frank Lüdicke, Cam Tuan Tran, Loyse Felber Medlin, Nicola Lama, Brindusa Taranu, Weeteck Ng, Christelle Haziza, Patrick Picavet, Gizelle Baker, Frank Lüdicke

Abstract

Background: The harm of smoking results mainly from long-term exposure to harmful and potentially harmful constituents (HPHCs) generated by tobacco combustion. Smoking cessation (SC) engenders favorable changes of clinical signs, pathomechanisms, and metabolic processes that together could reduce the harm of smoking-related diseases to a relative risk level approximating that of never-smokers over time. In most SC studies, the main focus is on the quitting rate of the SC program being tested. As there is limited information in the literature on short to multiple long-term functional or biological changes following SC, more data on short to mid-term favorable impacts of SC are needed.

Objective: The overall aim of the study was to assess the reversibility of the harm related to smoking over 1 year of continuous smoking abstinence (SA). This has been verified by assessing a set of biomarkers of exposure to HPHCs and a set of biomarkers of effect indicative of multiple pathophysiological pathways underlying the development of smoking-related diseases.

Methods: This multiregional (United States, Japan, and Europe), multicenter (42 sites) cohort study consisting of a 1-year SA period in an ambulatory setting was conducted from May 2015 to May 2017. A total of 1184 male and female adult healthy smokers, willing to quit smoking, were enrolled in the study. Nicotine replacement therapy (NRT) was provided for up to 3 months upon the subject's request. SC counseling and behavioral support were continuously provided. Biomarkers of exposure to HPHCs and biomarkers of effect were assessed in urine and blood at baseline, Month 3, Month 6, and Month 12. Cardiovascular biomarkers of effect included parameters reflecting inflammation (white blood cell), lipid metabolism (high-density lipoprotein cholesterol), endothelial function (soluble intercellular adhesion molecule-1), platelet function (11-dehydrothromboxane B2), oxidative stress (8-epi-prostaglandin F2 alpha), and carbon monoxide exposure (carboxyhemoglobin). Respiratory biomarkers of effect included lung function parameters and cough symptoms. The biomarkers of effect to evaluate genotoxicity (total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) and xenobiotic metabolism (cytochrome P450 2A6 activity) were also assessed. Continuous SA was verified at each visit following the actual quit date using self-reporting and chemical verification. Safety assessments included adverse events and serious adverse events, body weight, vital signs, spirometry, electrocardiogram, clinical chemistry, hematology and urine analysis safety panel, physical examination, and concomitant medications.

Results: In total, 1184 subjects (50.1% male) were enrolled; 30% of them quit smoking successfully for 1 year. Data analyses of the study results are ongoing and will be published after study completion.

Conclusions: This study provides insights into biological and functional changes and health effects, after continuous SA over 1 year. Study results will be instrumental in assessing novel alternative products to cigarettes considered for tobacco harm reduction strategies.

Trial registration: ClinicalTrials.gov NCT02432729; https://ichgcp.net/clinical-trials-registry/NCT02432729 (Archived by WebCite at http://www.webcitation.org/78QxovZrr).

International registered report identifier (irrid): DERR1-10.2196/12138.

Keywords: biomarkers; harm reduction; metabolic networks; pathways; smoking; smoking cessation; tobacco; tobacco products.

Conflict of interest statement

Conflicts of Interest: The study reported in this publication was solely funded by PMI. All authors are (or were) employees of PMI Research & Development (R&D) or worked for PMI R&D under contractual agreements.

©Cam Tuan Tran, Loyse Felber Medlin, Nicola Lama, Brindusa Taranu, Weeteck Ng, Christelle Haziza, Patrick Picavet, Gizelle Baker, Frank Lüdicke. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 07.06.2019.

Figures

Figure 1
Figure 1
Study design and timeline. Target quit date (TQD) was within 1-14 days after check out of Visit 2; actual quit date (AQD) was within 14 days after the TQD (grace period with occasional tobacco/nicotine use). Nicotine replacement therapy (NRT) was only permitted for up to three months + two weeks after the start date of NRT, which occurred at any time between the TQD and one week after the AQD. CC: cigarettes; SA: smoking abstinence; V: visit; W: week.
Figure 2
Figure 2
Flow chart of study participants.

References

    1. US Department of Health and Human Services Staff . How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Washington DC: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2010.
    1. World Health Organization . The Tobacco Atlas 2002. Geneva: World Health Organization; 2002.
    1. Waldum HL, Nilsen OG, Nilsen T, Rørvik H, Syversen V, Sanvik AK, Haugen OA, Torp SH, Brenna E. Long-term effects of inhaled nicotine. Life Sci. 1996;58(16):1339–46.
    1. Royal College of Physicians Royal College of Physicians. 2007. [2019-05-20]. Harm reduction in nicotine addiction: helping people who can't quit: a report by the Tobacco Advisory Group of the Royal College of Physicians .
    1. US Department of Health and Human Services Staff . How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-attributable Disease : a Report of the Surgeon General. Washington DC: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2010.
    1. Forey BA, Fry JS, Lee PN, Thornton AJ, Coombs KJ. The effect of quitting smoking on HDL-cholesterol - a review based on within-subject changes. Biomark Res. 2013 Sep 13;1(1):26. doi: 10.1186/2050-7771-1-26.
    1. Pezzuto A, Spoto C, Vincenzi B, Tonini G. Short-term effectiveness of smoking-cessation treatment on respiratory function and CEA level. J Comp Eff Res. 2013 May;2(3):335–43. doi: 10.2217/cer.13.25.
    1. Lee PN. The effect of reducing the number of cigarettes smoked on risk of lung cancer, COPD, cardiovascular disease and FEV(1)--a review. Regul Toxicol Pharmacol. 2013 Dec;67(3):372–81. doi: 10.1016/j.yrtph.2013.08.016.
    1. Wannamethee SG, Lowe GDO, Shaper AG, Rumley A, Lennon L, Whincup PH. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J. 2005 Sep;26(17):1765–73. doi: 10.1093/eurheartj/ehi183.
    1. Xu X, Weiss ST, Rijcken B, Schouten JP. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. Eur Respir J. 1994 Jun;7(6):1056–61.
    1. Saareks V, Ylitalo P, Alanko J, Mucha I, Riutta A. Effects of smoking cessation and nicotine substitution on systemic eicosanoid production in man. Naunyn Schmiedebergs Arch Pharmacol. 2001 May;363(5):556–61.
    1. Frost-Pineda K, Liang Q, Liu J, Rimmer L, Jin Y, Feng S, Kapur S, Mendes P, Roethig H, Sarkar M. Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. Nicotine Tob Res. 2011 Mar;13(3):182–93. doi: 10.1093/ntr/ntq235.
    1. Mobarrez F, Antoniewicz L, Bosson JA, Kuhl J, Pisetsky DS, Lundbäck M. The effects of smoking on levels of endothelial progenitor cells and microparticles in the blood of healthy volunteers. PLoS One. 2014;9(2):e90314. doi: 10.1371/journal.pone.0090314.
    1. Oguogho A, Lupattelli G, Palumbo B, Sinzinger H. Isoprostanes quickly normalize after quitting cigarette smoking in healthy adults. Vasa. 2000 May;29(2):103–5. doi: 10.1024/0301-1526.29.2.103.
    1. Rodu B. The scientific foundation for tobacco harm reduction, 2006-2011. Harm Reduct J. 2011 Jul 29;8:19. doi: 10.1186/1477-7517-8-19.
    1. Institute of Medicine . Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press; 2012.
    1. World Medical Association (WMA) World Medical Association. 2013. [2018-07-10]. Declaration of Helsinki - Ethical principles for medical research involving human subjects .
    1. ICH E6 (R2) 2016. [2018-07-10]. Integrated addendum to ICH E6 (R1): guideline for good clinical practice - Current Step 4 version dated 9 November 2016 .
    1. Zingg S, Collet T, Locatelli I, Nanchen D, Depairon M, Bovet P, Cornuz J, Rodondi N. Associations between cardiovascular risk factors, inflammation, and progression of carotid atherosclerosis among smokers. Nicotine Tob Res. 2016 Dec;18(6):1533–8. doi: 10.1093/ntr/ntv255.
    1. Reddy AV, Killampalli LK, Prakash AR, Naag S, Sreenath G, Biraggari SK. Analysis of lipid profile in cancer patients, smokers, and nonsmokers. Dent Res J (Isfahan) 2016;13(6):494–9.
    1. Moracco KE, Morgan JC, Mendel J, Teal R, Noar SM, Ribisl KM, Hall MG, Brewer NT. "My First Thought was Croutons": Perceptions of Cigarettes and Cigarette Smoke Constituents Among Adult Smokers and Nonsmokers. Nicotine Tob Res. 2016 Dec;18(7):1566–74. doi: 10.1093/ntr/ntv281.
    1. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983 Jun;51(3):390–5.
    1. Ashley DL, Burns D, Djordjevic M, Dybing E, Gray N, Hammond SK, Henningfield J, Jarvis M, Reddy KS, Robertson C, Zaatari G, WHO Study Group on Tobacco Product Regulation The scientific basis of tobacco product regulation. World Health Organ Tech Rep Ser. 2008;(951):1–277, 1 p following 277.
    1. US Food and Drug Administration. 2012. Guidance for industry - Reporting harmful and potentially harmful constituents in tobacco products and tobacco smoke under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act - Draft guidance .
    1. Haziza C, de La Bourdonnaye Guillaume, Skiada D, Ancerewicz J, Baker G, Picavet P, Lüdicke F. Evaluation of the Tobacco Heating System 2.2. Part 8: 5-Day randomized reduced exposure clinical study in Poland. Regul Toxicol Pharmacol. 2016 Nov 30;81(Suppl 2):S139–50. doi: 10.1016/j.yrtph.2016.11.003.
    1. Fagerström K, Russ C, Yu C, Yunis C, Foulds J. The Fagerström Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob Res. 2012 Dec;14(12):1467–73. doi: 10.1093/ntr/nts018.
    1. Ferguson J, Bauld L, Chesterman J, Judge K. The English smoking treatment services: one-year outcomes. Addiction. 2005 Apr;100(Suppl 2):59–69. doi: 10.1111/j.1360-0443.2005.01028.x.
    1. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, Tashkin DP, Lung Health Study Research Group Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):381–90. doi: 10.1164/ajrccm.161.2.9901044.
    1. SRNT Subcommittee on Biochemical Verification Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002 May;4(2):149–59. doi: 10.1080/14622200210123581.
    1. Berg CJ, Schauer GL, Ahluwalia JS, Benowitz NL. Correlates of NNAL levels among nondaily and daily smokers in the college student population. Curr Biomark Find. 2012 Oct 15;2012(2) doi: 10.2147/CBF.S34642.
    1. Schuit E, Panagiotou OA, Munafò MR, Bennett DA, Bergen AW, David SP. Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. Cochrane Database Syst Rev. 2017 Dec 8;9:CD011823. doi: 10.1002/14651858.CD011823.pub2.
    1. Graham AL, Zhao K, Papandonatos GD, Erar B, Wang X, Amato MS, Cha S, Cohn AM, Pearson JL. A prospective examination of online social network dynamics and smoking cessation. PLoS One. 2017;12(8):e0183655. doi: 10.1371/journal.pone.0183655.
    1. White MA, Ivezaj V, Grilo CM. Evaluation of a web-based cognitive behavioral smoking cessation treatment for overweight/obese smokers. J Health Psychol. 2017 Apr 1;:1359105317701560. doi: 10.1177/1359105317701560.
    1. Xu T, Holzapfel C, Dong X, Bader E, Yu Z, Prehn C, Perstorfer K, Jaremek M, Roemisch-Margl W, Rathmann W, Li Y, Wichmann HE, Wallaschofski H, Ladwig KH, Theis F, Suhre K, Adamski J, Illig T, Peters A, Wang-Sattler R. Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study. BMC Med. 2013 Mar 4;11:60. doi: 10.1186/1741-7015-11-60.
    1. Yoon C, Goh E, Park SM, Cho B. Effects of smoking cessation and weight gain on cardiovascular disease risk factors in Asian male population. Atherosclerosis. 2010 Jan;208(1):275–9. doi: 10.1016/j.atherosclerosis.2009.07.024.
    1. King CC, Piper ME, Gepner AD, Fiore MC, Baker TB, Stein JH. Longitudinal impact of smoking and smoking cessation on inflammatory markers of cardiovascular disease risk. Arterioscler Thromb Vasc Biol. 2017 Dec;37(2):374–9. doi: 10.1161/ATVBAHA.116.308728.
    1. Komiyama M, Shimada S, Wada H, Yamakage H, Satoh-Asahara N, Shimatsu A, Akao M, Morimoto T, Takahashi Y, Hasegawa K. Time-dependent changes of atherosclerotic LDL complexes after smoking cessation. J Atheroscler Thromb. 2016 Nov 1;23(11):1270–1275. doi: 10.5551/jat.34280. doi: 10.5551/jat.34280.
    1. Carmella SG, Chen M, Han S, Briggs A, Jensen J, Hatsukami DK, Hecht SS. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem Res Toxicol. 2009 Apr;22(4):734–41. doi: 10.1021/tx800479s.
    1. Theophilus EH, Coggins CR, Chen P, Schmidt E, Borgerding MF. Magnitudes of biomarker reductions in response to controlled reductions in cigarettes smoked per day: a one-week clinical confinement study. Regul Toxicol Pharmacol. 2015 Mar;71(2):225–34. doi: 10.1016/j.yrtph.2014.12.023.
    1. Iida M. Weight gain after smoking cessation and atherosclerotic low-density lipoprotein marker. J Atheroscler Thromb. 2016 Nov 1;23(11):1257–8. doi: 10.5551/jat.ED059. doi: 10.5551/jat.ED059.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj